A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis

Seminars in Arthritis and Rheumatism

Volumn 47, Issue 6, 2018, Pages 858-864

  Schiffenbauer, Adam ^a   Garg, Megha ^b   Castro, Christine ^b   Pokrovnichka, Angelina ^b   Joe, Galen ^c   Shrader, Joseph ^c   Cabalar, Imelda Victoria ^b   Faghihi Kashani, Sara ^a   Harris Love, Michael O ^c   Plotz, Paul H ^b   Miller, Frederick W ^a   Gourley, Mark ^b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Dermatomyositis; Infliximab; Polymyositis; TNF inhibitor

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; IMMUNOGLOBULIN G1 ANTIBODY; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR; DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BACKACHE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE EXACERBATION; DISEASE SEVERITY ASSESSMENT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYALGIA; PILOT STUDY; PLACEBO EFFECT; POLYMYOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; COMBINATION DRUG THERAPY; CROSSOVER PROCEDURE; DRUG ADMINISTRATION; MIDDLE AGED;

ADULT; CROSS-OVER STUDIES; DERMATOLOGIC AGENTS; DERMATOMYOSITIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISONE; TREATMENT OUTCOME;

EID: 85034788692     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2017.10.010     Document Type: Article

References (40)

1. Li, Y.P., Reid, M.B., Effect of tumor necrosis factor-alpha on skeletal muscle metabolism. Curr Opin Rheumatol 13 (2001), 483–487.
2. Albayda, J., Christopher-Stine, L., Novel approaches in the treatment of myositis and myopathies. Ther Adv Musculoskelet Dis 4 (2012), 369–377.
3. Aggarwal, R., Oddis, C.V., Therapeutic advances in myositis. Curr Opin Rheumatol 24 (2012), 635–641.
4. Efthimiou, P., Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications. Semin Arthritis Rheum 36 (2006), 168–172.
5. Dastmalchi, M., A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67 (2008), 1670–1677.
6. Hengstman, G.J., Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 50 (2003), 10–15.
7. Efthimiou, P., Schwartzman, S., Kagen, L.J., Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 65 (2006), 1233–1236.
8. Forsgren, S., Renstrom, L., Purdam, C., Gaida, J.E., TNF-alpha in the locomotor system beyond joints: high degree of involvement in myositis in a rabbit model. Int J Rheumatol, 2012, 2012, 637452.
9. Kuru, S., Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol 99 (2000), 585–588.
10. Mielnik, P., Chwalinska-Sadowska, H., Wiesik-Szewczyk, E., Maslinski, W., Olesinska, M., Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int 32 (2012), 639–643.
11. Shimizu, T., Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol 19 (2000), 352–359.
12. Lundberg, I., Brengman, J.M., Engel, A.G., Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol 63 (1995), 9–16.
13. De Bleecker, J.L., Meire, V.I., Declercq, W., Van Aken, E.H., Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord 9 (1999), 239–246.
14. Gabay, C., Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 37 (1994), 1744–1751.
15. Lundberg, I., Ulfgren, A.K., Nyberg, P., Andersson, U., Klareskog, L., Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40 (1997), 865–874.
16. Werth, V.P., Callen, J.P., Ang, G., Sullivan, K.E., Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol 119 (2002), 617–620.
17. Tews, D.S., Goebel, H.H., Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 55 (1996), 342–347.
18. Kuru, S., Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol 105 (2003), 217–224.
19. Higgs, B.W., Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients. Int J Rheum Dis 15 (2012), 25–35.
20. Pachman, L.M., TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 43 (2000), 2368–2377.
21. Hassan, A.B., Nikitina-Zake, L., Sanjeevi, C.B., Lundberg, I.E., Padyukov, L., Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum 50 (2004), 1013–1015.
22. Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292 (1975), 344–347.
23. Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292 (1975), 403–407.
24. Lundberg, I.E., Miller, F.W., Tjarnlund, A., Bottai, M., Diagnosis and classification of idiopathic inflammatory myopathies. J Intern Med 280 (2016), 39–51.
25. Rider, L.G., Defining clinical improvement in adult and juvenile myositis. J Rheumatol 30 (2003), 603–617.
26. Rider, L.G., Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 62 (2010), 465–472.
27. Rider, L.G., Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken) 63:Suppl. 11 (2011), S118–S157.
28. Harris-Love, M.O., Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford) 48 (2009), 134–139.
29. Kendall FP, M.E., Provance, G.P., Rodgers, M.M., Romani, W.A., Muscles Testing and Function with Posture and Pain, 5th ed, 2005, Lippincott Williams and Wilkins.
30. Jain, M., Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM). Phys Occup Ther Pediatr 26 (2006), 5–17.
31. Mann, H.F., Vencovský, J., Clinical trials roundup in idiopathic inflammatory myopathies. Curr Opin Rheumatol 23 (2011), 605–611.
32. Stubgen, J.P., Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies. J Neurol 258 (2011), 961–970.
33. De Paepe, B., Creus, K.K., De Bleecker, J.L., The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy. Clin Dev Immunol, 2012, 2012, 369432.
34. Riley, P., Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 47 (2008), 877–880.
35. Hengstman, G.J., Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 59 (2008), 159–163.
36. Sprott, H., Glatzel, M., Michel, B.A., Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. Rheumatology (Oxford) 43 (2004), 524–526.
37. Muscle Study G. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70 (2011), 427–436.
38. Hengstman, G.J.D., van den Hoogen, F.H.J., van Engelen, B.G.M., Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. European neurology 52 (2004), 61–63.
39. Urata, Y., Wakai, Y., Kowatari, K., Nitobe, T., Mizushima, Y., Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol 16 (2006), 410–411.
40. Musial, J., Undas, A., Celinska-Lowenhoff, M., Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 42 (2003), 1566–1568.